Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
October 14 2019 - 4:25PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical
company, today announced that it received a new Abbreviated New
Drug Application (ANDA) approval from the U.S. Food and Drug
Administration (FDA) for betamethasone dipropionate lotion USP
(augmented), 0.05%. The product is manufactured at Akorn’s
Amityville, New York manufacturing facility.
According to IQVIA, U.S. sales of betamethasone dipropionate
lotion (augmented), 0.05% were approximately $10 million for the
twelve months ended August 2019. Betamethasone dipropionate lotion
(augmented) is a corticosteroid indicated for the relief of the
inflammatory and pruritic manifestations of
corticosteroid-responsive dermatoses in patients 13 years of age or
older. About AkornAkorn, Inc. is a
specialty pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024